Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Therapy Type (Medication, Therapies & Supportive Care Devices, Stem Cell Therapy & Emerging Biologics); By Disease Type (Sporadic ALS, Familial ALS); By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies, Specialty Pharmacies & Home-Care Providers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

ALS Treatment Market: Genetic Precision and Disease Modification Reshape a High-Unmet-Need Landscape – (Updated On: 23rd-Sep-2026)

The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market was valued at USD 800 million in 2025 and is projected to reach USD 1.22 billion by 2032, expanding at a CAGR of 6.25% during 2026–2032, according to Strategic Market Research.

 

ALS treatment (also known as Lou Gehrig’s disease) is driven by the need for long-term disease management in a rapidly progressive neurological disorder where limited survival, high unmet medical need, and the absence of curative therapies continue to create demand for disease-modifying treatments. Most patients survive approximately 3–5 years after symptom onset, making early diagnosis and timely treatment important components of disease management.

 

Approximately 220,000–230,000 people are estimated to be living with ALS globally, while incidence generally stands at 1–2 new cases per 100,000 people annually. Around 30,000–35,000 people in the United States are estimated to have ALS, with approximately 5,000–6,400 new diagnoses each year.

 

Riluzole remains a foundational ALS therapy, extending survival by reducing glutamate-mediated neuronal damage. Edaravone, marketed as Radicava and Radicava ORS, is designed to slow functional decline, and more than 19,000 U.S. ALS patients have reportedly received edaravone since its initial FDA approval. Tofersen (Qalsody) represents a major shift toward genetically targeted treatment because it specifically addresses SOD1-associated ALS, a subtype representing only around 1%–2% of all ALS cases.

 

Overall, the ALS treatment market is evolving from predominantly symptom-oriented management toward disease-modifying and genetically targeted therapies. A defined global patient population, severe unmet clinical need, improved genetic testing, specialized ALS centers, and continued development of antisense, RNA-targeted and other precision therapies are strengthening the long-term commercial and clinical importance of ALS treatment.

 

Revenue Leaders and Growth Frontiers — Precision ALS Care Moves Beyond Broad Disease Management

Therapy Outlook — Established Medicines Lead as Emerging Biologics Build Momentum

Medication Anchors the Current ALS Treatment Revenue Base

Medication represents the leading segment in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market, accounting for 63% share with USD 504.0 million revenue in 2025 and expanding at a CAGR of 5.80% during 2026–2032. ALS medications are primarily focused on slowing disease progression, addressing genetic forms of the condition, and improving symptom management. Disease-modifying therapies such as riluzole help delay functional decline by reducing glutamate-related neuronal damage, while edaravone targets oxidative stress to preserve physical function. Targeted therapies such as tofersen address SOD1 gene mutations, whereas supportive medications including muscle relaxants, anticholinergics, and mood-management therapies improve quality of life for ALS patients.

Stem Cells and Emerging Biologics Open the Next Growth Frontier

Stem cell therapies and emerging biologics represent an advancing segment of the Amyotrophic Lateral Sclerosis (ALS) Treatment Market, focusing on neuroprotection, immune modulation, and genetic disease mechanisms rather than only symptom management. Valued at USD 112.0 million in 2025 with a 14% market share, this segment is projected to grow at a CAGR of 8.85%, supported by ongoing research into mesenchymal stem cells, antisense oligonucleotides, gene delivery platforms, and mutation-specific therapies aimed at slowing motor neuron degeneration. While these approaches remain investigational, they are expanding the future treatment pipeline for ALS.

 

Disease Outlook — Sporadic ALS Holds Scale as Genetic Subtypes Gain Commercial Relevance

Sporadic ALS Concentrates the Largest Addressable Treatment Population

Sporadic Amyotrophic Lateral Sclerosis (sALS) represents the dominant disease segment within the Amyotrophic Lateral Sclerosis Treatment Market, accounting for approximately 87.5% share with USD 700.0 million revenue in 2025 and expanding at a CAGR of 5.70% during 2026–2032. As nearly 90% of ALS cases occur sporadically without a known inherited cause, this segment forms the primary focus for broad-spectrum therapies, multidisciplinary care models, and clinical trials targeting common disease mechanisms such as neurodegeneration, oxidative stress, and abnormal protein accumulation.

Familial ALS Accelerates the Shift Toward Mutation-Specific Care

Familial Amyotrophic Lateral Sclerosis (fALS) represents a strategically important segment within the Amyotrophic Lateral Sclerosis Treatment Market, as genetic discoveries are accelerating the development of precision therapies targeting disease-causing mutations rather than only managing symptoms. Accounting for 12.5% of the market with USD 100.0 million revenue in 2025, the segment is expanding at a CAGR of 9.45%, supported by advances in gene-targeted approaches such as antisense oligonucleotides (ASOs), including tofersen for SOD1-mutated ALS. Identification of mutations such as SOD1, C9orf72, and FUS is enabling researchers to develop mutation-specific treatments while also improving understanding of molecular pathways involved in broader ALS progression.

 

Channel Outlook — Hospital Pharmacies Lead as Care Moves Closer to Home

Hospital Pharmacies Anchor Specialist-Led ALS Distribution

Hospital pharmacies represent a critical distribution and care-support channel in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market, accounting for 58.5% share with USD 468.0 million revenue in 2025 and expanding at a CAGR of 5.70%. These pharmacies support ALS treatment by managing specialized medications, coordinating access to emerging therapies, monitoring adverse effects, assisting with administration challenges, and improving medication adherence across inpatient and multidisciplinary neurology care settings.

Specialty Pharmacies and Home Care Gain Ground as Mobility Declines

Specialty and home-care channels are expanding as treatment shifts toward formulations that reduce hospital administration burden. FDA-approved Radicava ORS can be self-administered at home, either orally or through a feeding tube. The FDA specifically recognized the oral formulation as reducing the burden associated with intravenous administration. For patients progressively losing mobility, home-based pharmaceutical delivery, respiratory assistance, nutritional support and coordinated specialty care can reduce dependence on repeated facility visits.

 

Regional Outlook — North America Leads as Asia-Pacific Expands Treatment Access

North America Retains Leadership Through Specialist Access and Innovation

North America represents the leading regional market for Amyotrophic Lateral Sclerosis (ALS) Treatment, supported by advanced neurological care infrastructure, higher availability of specialized ALS clinics, early disease identification, and rapid adoption of emerging therapies. The region generated USD 300.0 million in revenue in 2025, accounting for 37.5% of the global ALS treatment market, and is projected to expand at a CAGR of 5.50% during 2026–2032. Growth is further supported by increasing demand for disease-modifying therapies, clinical research activity, and improved access to multidisciplinary ALS management programs.

Asia-Pacific Builds Momentum Through Expanding Neurological Capacity

Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market is witnessing steady expansion, accounting for a 25% market share with revenue of USD 200.0 million in 2025 and projected to grow at a CAGR of 7.65% during 2026–2032. Growth is supported by increasing diagnosis of ALS cases, expanding access to specialized neurological care, improving availability of disease-modifying therapies, and rising healthcare investments across countries such as Japan, China, South Korea, and India. The region’s aging population and gradual development of ALS-focused treatment infrastructure are further strengthening demand for long-term disease management solutions.

 

Competitive Landscape — Edaravone Scale Meets the Rise of RNA-Targeted ALS Pipelines

Mitsubishi Tanabe Pharma — Edaravone Scale Anchors Broad-Patient Treatment

Mitsubishi Tanabe Pharma has built a significant commercial position through RADICAVA (edaravone) and RADICAVA ORS, addressing the broader adult ALS population rather than a single genetic subtype. Intravenous RADICAVA received U.S. FDA approval in 2017, followed by oral RADICAVA ORS in 2022. The oral formulation is particularly relevant commercially because patients can self-administer it orally or through a feeding tube at home, reducing dependence on repeated IV administration.

Company-reported U.S. adoption provides a measurable indication of the franchise's reach. By June 2024, more than 16,000 people with ALS had received RADICAVA or RADICAVA ORS in the United States, representing over 1.9 million days of therapy, while more than 2,400 healthcare professionals had prescribed the treatments. RADICAVA ORS alone had treated more than 9,600 patients since its June 2022 U.S. launch. Edaravone has also received ALS-related approvals across markets including Japan, South Korea, Canada, Switzerland, Brazil and several Asian countries, extending Mitsubishi Tanabe's role beyond the U.S. market.

Biogen — QALSODY Moves Genetic ALS Treatment Into Clinical Practice

Biogen holds an important position in precision ALS therapy through QALSODY (tofersen), an antisense oligonucleotide developed for adults with SOD1-mutated ALS. FDA granted accelerated approval in April 2023, making QALSODY a targeted treatment for a defined genetic cause of ALS. SOD1 mutations account for approximately 2% of ALS cases, and FDA estimated the U.S. SOD1-ALS population at fewer than 500 patients, illustrating the highly specialized treatment population addressed by the drug.

QALSODY targets SOD1 mRNA to reduce SOD1 protein synthesis and was approved based on reduction in plasma neurofilament light, a biomarker of neuronal injury. Its regulatory footprint has subsequently expanded: Biogen reported approvals in the EU and China in 2024, followed by Canada and the UK in 2025. This makes Biogen particularly important to the market's transition from broad disease management toward genotype-directed ALS treatment.

Pipeline Competitors — Antisense and Genotype-Specific Programs Expand the Field

• Ionis Pharmaceuticals — RNA-therapeutics specialist behind important ALS antisense programs; its ulefnersen achieved a statistically significant Phase 3 FUSION primary endpoint in FUS-ALS in September 2026, including functional impairment and survival measures (p=0.0005).

• Otsuka Pharmaceutical — Holds an exclusive global license from Ionis to further develop and commercialize ulefnersen for FUS-ALS and initiated a global early-access program for eligible genetically confirmed patients in September 2026.

• Amylyx Pharmaceuticals — Developing AMX0114, an investigational antisense oligonucleotide targeting calpain-2; its Phase 1 LUMINA study is designed to enroll approximately 48 adults, with the first two 12-patient cohorts fully enrolled by mid-2026.

• Prilenia Therapeutics — Developing pridopidine for ALS; the pivotal PREVAiLS Phase 3 program is designed for approximately 500 participants across up to 60 ALS centers in 13 countries, targeting early, rapidly progressive ALS.

 

Analyst Perspective — Genetic Identification and Practical Delivery Define the Next ALS Market Phase

The amyotrophic lateral sclerosis treatment market is entering a more precision-driven phase as therapeutic development moves beyond broad disease management toward treatments designed around specific molecular and genetic pathways. The strongest opportunities are emerging around antisense technologies, gene-silencing approaches, biomarker-guided treatment selection, earlier genetic testing, and therapies capable of addressing defined ALS subtypes. At the same time, oral formulations, respiratory support, nutritional management, and home-based care are becoming increasingly important as treatment strategies focus on preserving patient independence throughout disease progression. Companies that can connect genetic identification with targeted therapies, measurable biomarkers, and practical long-term delivery models are positioned to shape the next stage of ALS care and create higher-value opportunities within this highly specialized neurological treatment market.

 

ALS Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 800 Million
Revenue Forecast in 2032	USD 1.22 Billion
Overall Growth Rate	CAGR of 6.25% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million/Billion, CAGR (2026–2032)
Segmentation	By Treatment / Therapy Type, By Disease Type, By Distribution Channel, By Geography
By Treatment / Therapy Type	Medication, Therapies & Supportive Care Devices, Stem Cell Therapy & Emerging Biologics
By Disease Type	Sporadic ALS, Familial ALS
By Distribution Channel	Hospital Pharmacies, Retail & Online Pharmacies, Specialty Pharmacies & Home-Care Providers
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	High unmet clinical need; increasing genetic testing; disease-modifying therapy adoption; antisense and RNA-targeted development; expansion of specialized ALS centers; growth of home-based care
Customization Option	Available upon request